[WSJ] How Much? Some Generic Drug Prices Are Skyrocketing: Analysis

A new analysis finds that half of all generic drugs sold through retailers became more expensive over the past 12 months. In fact, the prices paid by pharmacies more than doubled for one out of 11 generics. Read More

[WSJ] Paying for the Thousand-Dollar Pill

In The Wall Street Journal, AHIP President and CEO Karen Ignagni writes that Read More

[SFGate] At $1,000 a pill, Sovaldi will bankrupt us

How much can we afford to pay for one drug? How much profit does one company Read More

[The New York Times] $1,000 Hepatitis Pill Shows Why Fixing Health Costs Is So Hard

A new drug for the liver disease hepatitis C is scaring people. Read More

Gilead Can Afford to Take These Three Steps to Lower the Price of Sovaldi

Yesterday’s blockbuster earnings announcement from Gilead underscores how Read More

[SFGate] Gilead hepatitis C pill reaches $3.48 billion in quarterly sales

“The fundamental concern is Sovaldi and other speciality drugs are going Read More

[NCHC] Earnings Report Shows Gilead Can Lower Sovaldi’s Unsustainable Price

Statement from the National Coalition on Health Care’s President and CEO Read More

[SFGate] Costly hepatitis C drugs could add $300 to every American’s yearly premium, CVS says

Gilead Sciences’ new hepatitis C drug receives as much praise for its Read More

[Market Watch] CVS officials say Sovaldi pricing in line with history, but unsustainable

Gilead Sciences’ controversial $1,000-a-day Sovaldi pill is priced in line Read More

[The New York Times] $300,000 Drug

There is one other way that Kalydeco is an excellent example of personalized Read More

[SF Business Times ] Three takeaways from Gilead’s Hepatitis C challenge

1. It’s all about price — even when it’s not: Even before Foster Read More

[WSJ] Will Gilead’s Hepatitis C Drug Bust State Budgets?

Will the cost of new hepatitis C treatments bust state budgets? A new analysis Read More